Wells Fargo & Company Issues Positive Forecast for CONMED (NYSE:CNMD) Stock Price

CONMED (NYSE:CNMD) had its price objective boosted by Wells Fargo & Company from $41.00 to $42.00 in a research report report published on Thursday,Benzinga reports. They currently have an equal weight rating on the stock.

Other analysts have also recently issued reports about the stock. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of CONMED in a report on Wednesday, January 21st. Bank of America cut their price objective on shares of CONMED from $65.00 to $52.00 and set a “neutral” rating for the company in a research report on Monday, December 8th. JPMorgan Chase & Co. cut their price objective on shares of CONMED from $58.00 to $52.00 and set a “neutral” rating for the company in a research report on Thursday, November 6th. Piper Sandler decreased their target price on CONMED from $68.00 to $55.00 and set an “overweight” rating on the stock in a report on Thursday, November 6th. Finally, Zacks Research lowered CONMED from a “hold” rating to a “strong sell” rating in a report on Thursday, January 1st. One investment analyst has rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average target price of $52.83.

CONMED Stock Performance

CNMD stock opened at $37.35 on Thursday. The company has a debt-to-equity ratio of 0.85, a current ratio of 2.10 and a quick ratio of 0.95. CONMED has a 1 year low of $35.37 and a 1 year high of $74.70. The company has a market cap of $1.16 billion, a P/E ratio of 24.74, a price-to-earnings-growth ratio of 1.74 and a beta of 0.96. The stock’s fifty day moving average price is $41.43 and its 200-day moving average price is $46.43.

CONMED (NYSE:CNMD) last posted its quarterly earnings data on Wednesday, January 28th. The company reported $1.43 EPS for the quarter, beating analysts’ consensus estimates of $1.32 by $0.11. The company had revenue of $373.20 million during the quarter, compared to analysts’ expectations of $366.88 million. CONMED had a return on equity of 14.36% and a net margin of 3.42%.CONMED’s revenue for the quarter was up 7.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.34 earnings per share. On average, equities analysts forecast that CONMED will post 4.35 earnings per share for the current year.

Institutional Investors Weigh In On CONMED

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in CONMED by 2.0% during the fourth quarter. Vanguard Group Inc. now owns 3,684,439 shares of the company’s stock valued at $149,588,000 after acquiring an additional 73,533 shares during the period. Dimensional Fund Advisors LP grew its position in shares of CONMED by 19.8% during the third quarter. Dimensional Fund Advisors LP now owns 1,296,776 shares of the company’s stock worth $60,984,000 after purchasing an additional 214,126 shares in the last quarter. Wasatch Advisors LP purchased a new stake in shares of CONMED during the third quarter worth about $47,026,000. Deerfield Management Company L.P. raised its stake in CONMED by 8.6% during the 3rd quarter. Deerfield Management Company L.P. now owns 760,196 shares of the company’s stock valued at $35,752,000 after purchasing an additional 59,925 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in CONMED by 2.8% in the 2nd quarter. Geode Capital Management LLC now owns 734,529 shares of the company’s stock worth $38,259,000 after purchasing an additional 19,944 shares in the last quarter.

More CONMED News

Here are the key news stories impacting CONMED this week:

• Positive Sentiment: Q4 revenue and (adjusted) EPS beat consensus and sales rose ~7.9% year‑over‑year, showing recovery in surgical volumes. Strong top‑line performance is a primary driver of the positive headlines. CONMED Corporation Announces Fourth Quarter and Full-Year 2025 Financial Results
• Positive Sentiment: Gross margin improved and surgical (especially orthopedic) sales outperformed, giving management momentum to refocus the business and support 2026 strategy — a constructive signal for future profitability if trends continue. CONMED Stock Up Post Q4 Earnings and Revenue Beat, Gross Margin Up
• Positive Sentiment: Analysts and coverage note that orthopedic strength and a strategic refocus frame a constructive 2026 outlook, which could support medium‑term revenue and margin improvement if execution holds. CNMD Q4 Deep Dive: Ortho Outperformance and Strategic Refocusing Shape 2026 Outlook
• Neutral Sentiment: Wells Fargo nudged its price target slightly higher to $42 and kept an “equal weight” rating — a modest vote of confidence but not an upgrade that would typically spark strong buying. Benzinga
• Negative Sentiment: Some reported GAAP metrics were weaker: third‑party summaries highlighted a much lower GAAP diluted EPS figure and a sharp drop in net income and operating profit year‑over‑year, which raises near‑term earnings quality concerns. That contrast between adjusted and GAAP results is likely prompting investor caution. CONMED Corporation (CNMD) Stock Rises on Q4 2025 Earnings
• Negative Sentiment: Additional headwinds: higher intraday volume and recent insider selling, the stock trading below its 50‑ and 200‑day moving averages, and mixed analyst positions (some holds) have amplified selling pressure despite the beat. Conmed: Q4 Earnings Snapshot

CONMED Company Profile

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.